Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inspire Medical Systems (INSP) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Inspire Medical Systems (INSP) over the last 9 years, with Q4 2025 value amounting to 50.51%.

  • Inspire Medical Systems' EBITDA Margin rose 363000.0% to 50.51% in Q4 2025 from the same period last year, while for Dec 2025 it was 15.94%, marking a year-over-year increase of 93100.0%. This contributed to the annual value of 15.94% for FY2025, which is 93100.0% up from last year.
  • As of Q4 2025, Inspire Medical Systems' EBITDA Margin stood at 50.51%, which was up 363000.0% from 4.53% recorded in Q3 2025.
  • Inspire Medical Systems' EBITDA Margin's 5-year high stood at 50.51% during Q4 2025, with a 5-year trough of 40.24% in Q1 2021.
  • In the last 5 years, Inspire Medical Systems' EBITDA Margin had a median value of 4.36% in 2021 and averaged 3.9%.
  • As far as peak fluctuations go, Inspire Medical Systems' EBITDA Margin skyrocketed by 1659200bps in 2021, and later plummeted by -64500bps in 2025.
  • Inspire Medical Systems' EBITDA Margin (Quarter) stood at 3.11% in 2021, then skyrocketed by 180bps to 2.49% in 2022, then soared by 224bps to 8.06% in 2023, then soared by 76bps to 14.21% in 2024, then skyrocketed by 256bps to 50.51% in 2025.
  • Its EBITDA Margin was 50.51% in Q4 2025, compared to 4.53% in Q3 2025 and 1.58% in Q2 2025.